Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals

G Fiorillo; L Ibba; L Gargiulo; C A Vignoli; A Alfano; A Cortese; F Toso; D Orsini; P Iacovelli; P Frascione; A Narcisi; A Costanzo; M Valenti

doi:10.1111/jdv.19355

Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1444-e1446. doi: 10.1111/jdv.19355. Epub 2023 Jul 24.

Authors

G Fiorillo^{1

2}, L Ibba^{1

2}, L Gargiulo^{1

2}, C A Vignoli^{1

2}, A Alfano^{1

2}, A Cortese^{1

2}, F Toso^{1

2}, D Orsini³, P Iacovelli³, P Frascione⁴, A Narcisi², A Costanzo^{1

2}, M Valenti^{1

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
² Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
³ Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
⁴ Dermatology Oncology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.

PMID: 37458684
DOI: 10.1111/jdv.19355

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized
Biological Products*
Humans
Italy
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Biological Products